Schizophrenia.com

AbbVie's VRAYLAR® (cariprazine) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for the Treatment of Schizophrenia

everhopeful September 4, 2024, 8:57pm 1

1 Like

Topic		Replies	Views	Activity
AbbVie Announces Provincial Reimbursement for VRAYLAR® (cariprazine) for the Treatment of Schizophrenia in Québec Medications	1	296	April 17, 2023
AbbVie's VRAYLAR® (cariprazine) Now Publicly Reimbursed in Alberta Medications	1	51	September 15, 2025
FDA Approves VRAYLAR as Adjunctive Therapy for Major Depressive Disorder and AbbVie Announces Reimbursement Program in Canada Medications	0	230	June 7, 2023
CADTH Recommendation to Not Reimburse New Treatment a Failure for People Living with Schizophrenia (Canada, Vraylar) Medications	1	354	September 22, 2022
New schizophrenia treatment option now publicly covered in Alberta Medications	0	60	September 25, 2025